Clin2
NCT07423546Likely a fitRecruiting

Brain scan study of Cobenfy in schizophrenia

SCHIZOPHRENIA 1 (Disorder)Schizoaffecitve Disorder

Treatments studied

Part of Mental health clinical trials.

This study tests a new medication called Cobenfy (also known as trospium) using brain scans to see how it affects dopamine in people with schizophrenia. If you have schizophrenia and are not currently on antipsychotics, you may be able to join.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
12 people
Ages
18 years to 50 years
Study type
Interventional

Who can take part

  • You are between 18 and 50 years old.
  • You have schizophrenia, schizoaffective disorder, or schizophreniform disorder.
  • You are not currently taking any antipsychotic medication and have been off it for at least 3 weeks (4 weeks for certain meds).
  • Your symptoms are moderate (not too mild, not too severe).
  • You are willing to use effective birth control if you're a woman who could become pregnant.
  • You have not used nicotine (cigarettes, vaping, etc.) in the past month.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07850102Not yet recruiting· Phase 2
Brain scans for schizophrenia in adults

This study uses brain scans (MRI) to look at brain activity in people with schizophrenia. It helps researchers understand the condition better, and you do not receive any treatment.

Baltimore, Maryland
NCT07715253Not yet recruiting· Phase 1
Brain scans to study dopamine receptors in schizophrenia

This study looks at how a specific type of brain receptor (dopamine-3) works in people with schizophrenia using special brain scans (PET). Researchers want to see how these receptors behave when you are not taking antipsychotic medication, which may help guide future treatments.

NCT07624227Recruiting· Phase 1/Phase 2
Cobenfy Maintenance Effects on Cocaine Use Disorder

This study tests whether a medication called Cobenfy can reduce cocaine's effects in people with cocaine use disorder. Researchers will monitor your health and test how the medication impacts your response to cocaine.

Lexington, Kentucky
NCT04038840Recruiting· Phase 1
Brain PET-MR imaging to study schizophrenia connections

This early (Phase 1) study uses a special brain scan to look at synapses—the contact points between brain cells—in people with schizophrenia-related conditions. It helps researchers understand brain activity and connection patterns, which may guide future tests or treatments.

Palo Alto, California
NCT07626034Not yet recruiting· Phase 1/Phase 2
Brain scan study for schizophrenia treatment

This study uses a special brain scan to see how well a new medication attaches to brain receptors. It may help find better treatments for schizophrenia.

NCT03911726Recruiting
Brain imaging study of antipsychotic effects in schizophrenia

This study uses PET and MRI scans to see how antipsychotic medications affect the brain's dopamine system in people with schizophrenia, compared to healthy individuals. It may help understand if these medications cause changes that lead to worsening symptoms over time.

Mannheim, Baden-Wurttemberg

Hear when a new SCHIZOPHRENIA 1 (Disorder) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.